Annual report pursuant to Section 13 and 15(d)


12 Months Ended
Apr. 30, 2021
Commitments and Contingencies Disclosure [Abstract]  



The Company acquires assets still in development and enters R&D arrangements with third parties that often require milestone and royalty payments to the third-party contingent upon the occurrence of certain future events linked to the success of the asset in development. Milestone payments may be required, contingent upon the successful achievement of an important point in the development lifecycle of the pharmaceutical product (e.g., approval of the product for marketing by a regulatory agency). If required by the license agreements, the Company may have to make royalty payments based upon a percentage of the sales of the pharmaceutical products if regulatory approval for marketing is obtained.


Office Lease


Effective September 1, 2017, the Company entered into a lease for its office space in California. The term of the lease is for 24 months and expired on August 31, 2019. In May 2019, the Company entered into an additional one-year lease for the Leased Premises, commencing upon the expiration of the term of the prior lease. The term of the lease expired on August 31, 2020.


On May 28, 2020, the Company entered into an additional six-month lease of the office space, commencing on September 1, 2020. The term of the new lease expired on February 28, 2021.


On May 24, 2021, the Company entered into an additional six-month lease of the office space, commencing on September 1, 2021 and which expires on February 28, 2022.


Rent expenses for these offices for the years ended April 30, 2021 and 2020 were $20,429 and $30,964, respectively.


The following table summarizes the Company’s aggregate future minimum lease payments required under the operating lease as of.


Years Ending April 30,   Amount  
2022   $ 12,390  
    $ 12,390  


Material Agreements


The Company’s material agreements are identified and summarized in Note 1 – Nature of Business – Company Background.


Compensation Agreements


The Company entered into executive compensation agreements with its three executive officers in March 2015, each of which was amended in December 2015 and March 2017. Each agreement has a term of two years with annual extensions thereafter unless the Company or the officer provides written notification of termination at least ninety days prior to the end of the term or subsequent extensions. The Company also entered a compensation agreement with a Board member in April 2015 which continued in effect until amended in May 2017.


In May 2017, the Company amended the compensation agreement with the Board members and the terms continue in effect until a member is no longer on the Board.


The Company has four independent directors. Each director receives the same compensation: (i) $12,500 in cash for each calendar quarter of service on the Board; (ii) 333 fully-paid, non-assessable shares of the Company’s restricted common stock (“Shares”) annually; and (iii) a five-year option to purchase 333 Shares annually at an exercise price equal to the fair market value of the Shares on the date of grant. The Shares and the option Shares fully vest on the date of the grants.